Mitochondrial superoxide levels were decreased in cells overexpressing STX17-DT after treated with axitinib, indicating that STX17-DT might protect RCC cells from axitinib-induced cell death through inhibiting reactive oxygen species and lipid peroxide accumulation in mitochondria (Figs. 4B and S4A). This evidence concerns the gene STX17 and renal cell carcinoma.